The Metabolic Syndrome and thrombolysing stroke patients
In a study from University of Helsinki published recently ( Stroke. 2009;40:337.) the authors concluded that metabolic syndrome as well as its individual components predicted the incidence of the ischaemic stroke and the coronary heart disease equally well and should be treated equally as well.
But what is about the effect of the metabolic syndrome on thrombolysing stroke patients? Arenillas et al tried to answer this question by prospectively studying consecutive ischaemic stroke patients, treated with intravenous tissue-type plasminogen activator according to SITS-MOST criteria, with an MCA occlusion on prebolus transcranial Doppler examination ( Stroke. 2009;40:344).
The assumption is that metabolic syndrome (MetS) might confer a higher resistance to intravenous thrombolysis in acute middle cerebral artery (MCA) ischaemic stroke. MetS increases the risk of stroke in women to a greater extent than in men.